Physician profile
Mark Azbel
NPI 1306847405
$8,075.64
in general payments reported to CMS, 2019-2025
32 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,695 · 2020: $744 · 2021: $1,588 · 2022: $1,199 · 2023: $843 · 2024: $986 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,811 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,811.28 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,819.19 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,321.62 | 2019-2025 | Linzess, Viberzi |
| Amarin Pharma, INC. | $603.55 | 2019-2022 | |
| Allergan, INC. | $521.40 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $459.54 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $430.60 | 2019-2024 | Eliquis, Camzyos |
| Sumitomo Pharma America, INC. | $326.84 | 2024-2025 | Gemtesa |
| Ironwood Pharmaceuticals, INC | $310.01 | 2019-2024 | Linzess |
| Novartis Pharmaceuticals Corporation | $294.55 | 2019-2023 | |
| Aimmune Therapeutics, INC. | $265.49 | 2024 | |
| Merck Sharp & Dohme LLC | $236.54 | 2021-2024 | Verquvo, Belsomra, Lagevrio |
| Novo Nordisk INC | $233.80 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $225.72 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $171.01 | 2023-2025 | Rexulti, Nuedexta |
| Amneal Pharmaceuticals LLC | $167.22 | 2022-2024 | Unithroid |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $123.28 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $85.50 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $78.06 | 2019-2025 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $47.75 | 2019 | |
| Lundbeck LLC | $38.54 | 2025 | Rexulti |
| Amgen INC. | $37.87 | 2024-2025 | Repatha, Otezla, Otezla |
| Almatica Pharma LLC | $37.10 | 2022 | |
| Pfizer INC. | $37.03 | 2020-2023 | |
| Lilly USA, LLC | $35.54 | 2019-2021 | |
| Ardelyx, INC. | $27.43 | 2024 | Ibsrela |
| Glaxosmithkline, LLC. | $25.00 | 2019 | |
| Endo Pharmaceuticals INC. | $24.73 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $21.88 | 2019 | |
| Advanced Oxygen Therapy INC. | $17.78 | 2025 | Topical Oxygen Chamber For Extremities |
| Astellas Pharma US INC | $17.31 | 2019 | |
| Scilex Pharmaceuticals INC. | $16.94 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Azbel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.